 Melissa Wilson
Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 13 | 2025 | 2828 | 1.160 |
Why?
| | Healthy Aging | 2 | 2024 | 35 | 0.940 |
Why?
| | Patient Dropouts | 1 | 2025 | 67 | 0.930 |
Why?
| | Exercise Therapy | 3 | 2024 | 436 | 0.810 |
Why?
| | Exercise | 6 | 2024 | 2043 | 0.760 |
Why?
| | Self Efficacy | 1 | 2024 | 393 | 0.700 |
Why?
| | Aging | 4 | 2024 | 1861 | 0.560 |
Why?
| | Health Personnel | 1 | 2022 | 701 | 0.490 |
Why?
| | Stress, Psychological | 1 | 2022 | 1097 | 0.430 |
Why?
| | Melanoma | 4 | 2023 | 757 | 0.410 |
Why?
| | Frailty | 2 | 2023 | 169 | 0.320 |
Why?
| | Macaca mulatta | 2 | 2024 | 166 | 0.260 |
Why?
| | Pyridones | 2 | 2024 | 168 | 0.240 |
Why?
| | Absorptiometry, Photon | 1 | 2025 | 254 | 0.220 |
Why?
| | Bias | 1 | 2025 | 218 | 0.220 |
Why?
| | Chromosomes, Human, Y | 1 | 2023 | 24 | 0.210 |
Why?
| | Alanine | 1 | 2024 | 152 | 0.210 |
Why?
| | Data Interpretation, Statistical | 1 | 2025 | 363 | 0.210 |
Why?
| | Humans | 30 | 2025 | 136764 | 0.200 |
Why?
| | Neurofibromatosis 1 | 1 | 2023 | 52 | 0.200 |
Why?
| | Genetic Variation | 2 | 2025 | 985 | 0.200 |
Why?
| | Tenofovir | 1 | 2024 | 243 | 0.190 |
Why?
| | Activities of Daily Living | 2 | 2023 | 413 | 0.190 |
Why?
| | Osteoporosis | 1 | 2025 | 243 | 0.190 |
Why?
| | Morals | 1 | 2022 | 81 | 0.180 |
Why?
| | Bone Density | 1 | 2025 | 487 | 0.180 |
Why?
| | Computer Simulation | 1 | 2025 | 973 | 0.170 |
Why?
| | Transcriptome | 2 | 2024 | 969 | 0.170 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5742 | 0.170 |
Why?
| | Social Stigma | 1 | 2022 | 134 | 0.170 |
Why?
| | Guideline Adherence | 1 | 2025 | 546 | 0.170 |
Why?
| | Kidney Diseases | 1 | 2025 | 407 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 135 | 0.170 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 85 | 0.170 |
Why?
| | Education, Distance | 1 | 2021 | 48 | 0.170 |
Why?
| | Heart Rate | 1 | 2024 | 820 | 0.170 |
Why?
| | Weight Gain | 1 | 2024 | 519 | 0.170 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 116 | 0.170 |
Why?
| | Heterografts | 2 | 2017 | 138 | 0.170 |
Why?
| | Sequence Analysis, DNA | 1 | 2023 | 809 | 0.170 |
Why?
| | Occupational Therapy | 1 | 2022 | 100 | 0.160 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 116 | 0.160 |
Why?
| | Sarcopenia | 1 | 2021 | 83 | 0.160 |
Why?
| | Body Composition | 2 | 2021 | 679 | 0.160 |
Why?
| | Aged | 9 | 2025 | 23794 | 0.150 |
Why?
| | Interleukin-10 | 1 | 2021 | 302 | 0.150 |
Why?
| | Sex Characteristics | 1 | 2024 | 759 | 0.150 |
Why?
| | Research Design | 1 | 2025 | 1127 | 0.150 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2018 | 25 | 0.150 |
Why?
| | Genomics | 1 | 2023 | 790 | 0.140 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2829 | 0.140 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 283 | 0.130 |
Why?
| | Middle Aged | 9 | 2025 | 33228 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1467 | 0.130 |
Why?
| | Mass Screening | 1 | 2025 | 1267 | 0.130 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 351 | 0.130 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1428 | 0.130 |
Why?
| | Pre-Eclampsia | 1 | 2018 | 189 | 0.120 |
Why?
| | Genome | 1 | 2017 | 294 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2184 | 0.120 |
Why?
| | Muscle, Skeletal | 2 | 2023 | 1710 | 0.120 |
Why?
| | Male | 12 | 2025 | 67309 | 0.120 |
Why?
| | Female | 13 | 2025 | 72787 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 868 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3264 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2022 | 1163 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 697 | 0.100 |
Why?
| | Inflammation | 2 | 2021 | 2834 | 0.100 |
Why?
| | Microbiota | 1 | 2021 | 762 | 0.100 |
Why?
| | Telemedicine | 1 | 2022 | 851 | 0.100 |
Why?
| | Brain | 1 | 2024 | 2664 | 0.100 |
Why?
| | DNA | 1 | 2018 | 1458 | 0.090 |
Why?
| | Blood Pressure | 1 | 2018 | 1774 | 0.090 |
Why?
| | Quality of Life | 2 | 2022 | 2878 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2025 | 15504 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2412 | 0.080 |
Why?
| | Genotype | 2 | 2025 | 1914 | 0.060 |
Why?
| | Adult | 7 | 2024 | 37630 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7585 | 0.060 |
Why?
| | Bone Diseases, Metabolic | 1 | 2025 | 62 | 0.060 |
Why?
| | Aminobutyrates | 1 | 2024 | 35 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 54 | 0.050 |
Why?
| | Segmental Duplications, Genomic | 1 | 2023 | 8 | 0.050 |
Why?
| | Tandem Repeat Sequences | 1 | 2023 | 21 | 0.050 |
Why?
| | DNA, Satellite | 1 | 2023 | 18 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1613 | 0.050 |
Why?
| | HIV Integrase Inhibitors | 1 | 2024 | 70 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2023 | 16 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2023 | 20 | 0.050 |
Why?
| | Heterochromatin | 1 | 2023 | 53 | 0.050 |
Why?
| | Reference Standards | 1 | 2023 | 186 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 147 | 0.050 |
Why?
| | Multigene Family | 1 | 2023 | 198 | 0.050 |
Why?
| | Solitary Nucleus | 1 | 2022 | 23 | 0.050 |
Why?
| | Los Angeles | 1 | 2022 | 76 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2025 | 304 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2023 | 113 | 0.050 |
Why?
| | Viral Load | 1 | 2024 | 464 | 0.050 |
Why?
| | Genetics, Population | 1 | 2023 | 209 | 0.050 |
Why?
| | Adenine | 1 | 2024 | 270 | 0.050 |
Why?
| | Hospitalization | 2 | 2022 | 2183 | 0.050 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 10 | 0.050 |
Why?
| | Alleles | 1 | 2025 | 890 | 0.050 |
Why?
| | Psoas Muscles | 1 | 2021 | 13 | 0.050 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 42 | 0.050 |
Why?
| | Taxoids | 1 | 2021 | 102 | 0.050 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 60 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 42 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 5701 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 87 | 0.040 |
Why?
| | Social Environment | 1 | 2022 | 295 | 0.040 |
Why?
| | Telomere | 1 | 2023 | 280 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2024 | 488 | 0.040 |
Why?
| | Actigraphy | 1 | 2020 | 110 | 0.040 |
Why?
| | Base Sequence | 1 | 2023 | 2179 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 7572 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 346 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 657 | 0.040 |
Why?
| | Animals | 4 | 2024 | 36823 | 0.040 |
Why?
| | DNA Methylation | 1 | 2023 | 640 | 0.040 |
Why?
| | Patient Compliance | 1 | 2022 | 577 | 0.040 |
Why?
| | HIV-1 | 1 | 2024 | 863 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 535 | 0.030 |
Why?
| | Inpatients | 1 | 2022 | 496 | 0.030 |
Why?
| | Anti-HIV Agents | 1 | 2024 | 775 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 672 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2017 | 113 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 549 | 0.030 |
Why?
| | Europe | 1 | 2018 | 413 | 0.030 |
Why?
| | Oncogenes | 1 | 2017 | 116 | 0.030 |
Why?
| | Fatigue | 1 | 2019 | 327 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 778 | 0.030 |
Why?
| | Machine Learning | 1 | 2021 | 487 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1242 | 0.030 |
Why?
| | Students | 1 | 2021 | 622 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 716 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 320 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 1065 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2605 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 776 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5423 | 0.030 |
Why?
| | Prognosis | 1 | 2021 | 4013 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1682 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2792 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2667 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3540 | 0.020 |
Why?
| | Mice | 2 | 2017 | 17733 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1395 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4190 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2017 | 3405 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3188 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4143 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2639 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3946 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 6728 | 0.010 |
Why?
| | United States | 1 | 2018 | 14691 | 0.010 |
Why?
|
|
Wilson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|